Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 182

Cited In for PubMed (Select 15254063)


Focus on PTEN Regulation.

Bermúdez Brito M, Goulielmaki E, Papakonstanti EA.

Front Oncol. 2015 Jul 27;5:166. doi: 10.3389/fonc.2015.00166. eCollection 2015. Review.


Ghrelin inhibition of ethanol-induced gastric epithelial cell apoptosis is mediated by miR-21.

Jiang M, Gao PF, Li HQ, Tian PY, Fan XM.

Int J Clin Exp Pathol. 2015 May 1;8(5):4662-72. eCollection 2015.


miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN.

Xie X, Liu HT, Mei J, Ding FB, Xiao HB, Hu FQ, Hu R, Wang MS.

Int J Clin Exp Pathol. 2015 Apr 1;8(4):3827-34. eCollection 2015.


Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response.

Yeo W, Chan SL, Mo FK, Chu CM, Hui JW, Tong JH, Chan AW, Koh J, Hui EP, Loong H, Lee K, Li L, Ma B, To KF, Yu SC.

BMC Cancer. 2015 May 12;15:395. doi: 10.1186/s12885-015-1334-6.


Increase in apoptosis by combination of metformin with silibinin in human colorectal cancer cells.

Tsai CC, Chuang TW, Chen LJ, Niu HS, Chung KM, Cheng JT, Lin KC.

World J Gastroenterol. 2015 Apr 14;21(14):4169-77. doi: 10.3748/wjg.v21.i14.4169.


PTEN: Multiple Functions in Human Malignant Tumors.

Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F, Ciuffreda L.

Front Oncol. 2015 Feb 16;5:24. doi: 10.3389/fonc.2015.00024. eCollection 2015. Review.

Free PMC Article

Autophagy in malignant transformation and cancer progression.

Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine B, Maiuri MC, Martin SJ, Penninger J, Piacentini M, Rubinsztein DC, Simon HU, Simonsen A, Thorburn AM, Velasco G, Ryan KM, Kroemer G.

EMBO J. 2015 Apr 1;34(7):856-80. doi: 10.15252/embj.201490784. Epub 2015 Feb 23. Review.


Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition.

Mehta M, Khan A, Danish S, Haffty BG, Sabaawy HE.

Mol Cancer Ther. 2015 May;14(5):1171-80. doi: 10.1158/1535-7163.MCT-14-0708. Epub 2015 Feb 18.


mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions.

Showkat M, Beigh MA, Andrabi KI.

Mol Biol Int. 2014;2014:686984. doi: 10.1155/2014/686984. Epub 2014 Nov 20. Review.


Estrogen receptors in prostate development and cancer.

Yeh CR, Da J, Song W, Fazili A, Yeh S.

Am J Clin Exp Urol. 2014 Jul 12;2(2):161-8. eCollection 2014. Review.


First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, Mazina K, Lin R, Wu J, Fredrickson J, Spoerke JM, Lackner MR, Yan Y, Friedman LS, Kaye SB, Derynck MK, Workman P, de Bono JS.

Clin Cancer Res. 2015 Jan 1;21(1):77-86. doi: 10.1158/1078-0432.CCR-14-0947. Epub 2014 Nov 4.


Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma.

Duman BB, Kara OI, Uğuz A, Ates BT.

Contemp Oncol (Pozn). 2014;18(4):234-40. doi: 10.5114/wo.2014.43803. Epub 2014 Jul 4.


miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator.

Zhu H, Han C, Lu D, Wu T.

Am J Pathol. 2014 Oct;184(10):2828-39. doi: 10.1016/j.ajpath.2014.06.024.


PTEN hopping on the cell membrane is regulated via a positively-charged C2 domain.

Yasui M, Matsuoka S, Ueda M.

PLoS Comput Biol. 2014 Sep 11;10(9):e1003817. doi: 10.1371/journal.pcbi.1003817. eCollection 2014 Sep.


The mTOR signaling pathway as a treatment target for intracranial neoplasms.

Pachow D, Wick W, Gutmann DH, Mawrin C.

Neuro Oncol. 2015 Feb;17(2):189-99. doi: 10.1093/neuonc/nou164. Epub 2014 Aug 27. Review.


Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway.

Ghebeh H, Al-Khaldi S, Olabi S, Al-Dhfyan A, Al-Mohanna F, Barnawi R, Tulbah A, Al-Tweigeri T, Ajarim D, Al-Alwan M.

Br J Cancer. 2014 Oct 14;111(8):1552-61. doi: 10.1038/bjc.2014.453. Epub 2014 Aug 12.


Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer.

Wang H, Xu C, Kong X, Li X, Kong X, Wang Y, Ding X, Yang Q.

PLoS One. 2014 Jun 6;9(6):e99067. doi: 10.1371/journal.pone.0099067. eCollection 2014.


The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder.

Sfakianos JP, Lin Gellert L, Maschino A, Gotto GT, Kim PH, Al-Ahmadie H, Bochner BH.

Urol Oncol. 2014 Jul;32(5):657-62. doi: 10.1016/j.urolonc.2014.02.003. Epub 2014 May 16.


The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis.

Cai J, Xu L, Tang H, Yang Q, Yi X, Fang Y, Zhu Y, Wang Z.

Oncologist. 2014 May;19(5):528-35. doi: 10.1634/theoncologist.2013-0333. Epub 2014 Apr 9.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk